Idarubicin
This anthracycline chemotherapy drug works by inserting into DNA strands and inhibiting topoisomerase II, interfering with cancer cell DNA replication and causing cell death. It is used primarily to treat acute myeloid leukemia (AML) and some other leukemias. Cardiac toxicity is a significant concern, and cumulative dose limits must be observed.
Molecular Weight
497.5000 g/mol
LogP
1.90
TPSA
177.00 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
2D Structure
Cite this structure
Embed this structure
SMILES
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
InChI
InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
Molecular Formula
C26H27NO9
HBD / HBA
5 / 10
Rotatable Bonds
3
Heavy Atoms
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This anthracycline chemotherapy drug works by inserting into DNA strands and inhibiting topoisomerase II, interfering with cancer cell DNA replication and causing cell death. It is used primarily to treat acute myeloid leukemia (AML) and some other leukemias. Cardiac toxicity is a significant concern, and cumulative dose limits must be observed.
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.
Yes, Idarubicin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1117. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 42890. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="idarubicin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/idarubicin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/idarubicin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/idarubicin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="idarubicin"></drugfyi-drug>